← Issue №13/ week of Sep 27, 2026/Hepatology

EBV-reactive KIR+ CX3CR1+ CD8+ T cells mediate liver transplantation tolerance.

From GI Signals issue №13: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=20 · Sep 23, 2026 · J Hepatology · IF 40.1

EBV-reactive KIR+ CX3CR1+ CD8+ T cells mediate liver transplantation tolerance.

Basic sciencebasic sciencetranslationalbiomarkerpediatric
Clinical takeawayNo clinical action yet: a mechanistic finding in mice and in vitro studies, with preliminary human data in a small pediatric trial (n=20).
What it foundEBV-derived peptides presented by HLA-E on alloreactive CD4+ T cells prime KIR+ CX3CR1+ CD8+ T cells, which suppress alloreactive CD4+ T cells via perforin and granzyme B, promoting liver transplant tolerance.
ContextOpens a new question on the role of EBV and KIR+ CX3CR1+ CD8+ T cells in liver transplant tolerance, a previously unclear mechanism.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Liu Y … Xia Q · Journal of Hepatology · IF 40.1 · PubMed ↗Permalink
← Read the whole of issue №13 Every paper GI Signals surfaces gets a page like this one. All issues